Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

BMS, AbbVie nab 'breakthrough' tag for multiple myeloma-fighting antibody

A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.

Bristol-Myers and AbbVie speed toward FDA approval with a 'breakthrough' cancer drug

A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.

UPDATED: J&J-Bayer and Pfizer-BMS look for marketing advantages in real-world Xarelto, Eliquis data

Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.

Bristol-Myers forges $1.25B deal to beef up fibrosis pipeline in Promedior buyout

Bristol-Myers Squibb has landed the rights to buy out Lexington, MA-based Promedior, paying $150 million upfront and committing a total of $1.25 billion to the deal--if the biotech's fibrosis drug comes through in Phase II studies.

Patient education 'useless' when it comes to Eliquis adherence: study

Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant, Eliquis, atrial fibrillation patients posted adherence rates near 90%. And the icing on the cake? The company didn't need to shell out on patient education to get them there.

Bristol-Myers JV licenses immuno-oncology assets from Yale

The joint venture between Bristol-Myers Squibb and Allied Minds has picked up the rights to an immuno-oncology platform and associated lead molecules from Yale University. Having struck the deal, Allied-Bristol Life Sciences is to work on turning Yale's research into antibody recruiting molecules into drug development programs that are ready for the clinic.

Bristol-Myers, Sanofi catch a break in Plavix marketing case

Bristol-Myers Squibb and Sanofi scored a victory in a False Claims Act marketing case over its blood-thinner, Plavix, as a federal judge in New Jersey tossed out some allegations from a former Sanofi sales rep that the company made misleading statements about the med to gain more Medicare and Medicare coverage.

Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

The first half of the year has provided a good ride for Big Pharma and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market meltdown and saw values rise 23%. But, of course, averages come from the highs and the lows and some players have actually seen share price declines during this bull market.

Merck's Keytruda ready for quick FDA action on big melanoma expansion

Merck & Co.'s Keytruda has jumped on the FDA's priority review track for a new first-line use in melanoma. The PD-1 immunotherapy, already approved to treat relapsed melanoma and under FDA review in lung cancer, needs the broader melanoma approval to keep abreast of Bristol-Myers Squibb's rival drug Opdivo.

BMS revives Orencia DTC advertising after two-year absence

An old drug with a new trick? We'll see. After a long DTC hiatus, Bristol-Myers Squibb is taking a new tack with advertising its rheumatoid arthritis drug Orencia. The campaign for the decade-old drug emphasizes long-term relief and uses the new tagline, "See your RA in a different way."